ABSTRACT
AIM: As parents and caregivers are responsible for the oral health of children, their own dental anxiety may negatively impact the oral health of their children. This study aimed to assess whether parental dental anxiety and knowledge of caries preventive measures are associated with their psychological profiles and their children's oral health. METHODS: This case-control study involved parents, who were divided according to whether their children did or did not have active caries. The differences in Short version of the Dental Anxiety Inventory, and Knowledge of Caries Preventive Measures (KCPM) scores between the parents whose children have and do not have active caries was established by the Mann-Whitney U test (P < 0.05). CONCLUSION: Parental dental anxiety and knowledge of caries preventive measures are associated with the oral health of their children.
Subject(s)
Dental Anxiety , Oral Health , Case-Control Studies , Child , Cross-Sectional Studies , Dental Anxiety/prevention & control , Dental Caries Susceptibility , Humans , Parents/psychologyABSTRACT
Glioblastomas are radiation-resistant tumours which react only rarely to radiotherapy. Radiotherapy was employed in such cases only where the condition was not clinically dramatic or terminal. A certain degree of improvement was noted in the patients who had been selected in this manner. Chemotherapy has not yielded any success to date.
Subject(s)
Brain Neoplasms/surgery , Cerebral Cortex/surgery , Glioma/surgery , Adolescent , Adult , Aged , Brain Neoplasms/diagnosis , Child , Dominance, Cerebral , Female , Glioma/diagnosis , Humans , Male , Middle Aged , Postoperative Complications/mortality , PrognosisSubject(s)
Intervertebral Disc Displacement/surgery , Adolescent , Adult , Aged , Child , Female , Humans , Intervertebral Disc Displacement/diagnosis , Lumbar Vertebrae , Male , Middle AgedABSTRACT
The aim of this study was to examine antitumorigenic Cis DDP properties in metastatic brain tumors. Thirty-four untreated patients with brain metastases recorded by CAT scans or radionuclide scans plus neurological examinations underwent the treatment. Pathohistology of primary tumors mainly showed breast [8] and lung [8] carcinomas and melanomas [10]. Other localizations of primary tumors were infrequent. Cis DDP was administered in doses of 30 mg/m2 body surface daily over 4 days. All the patients received at least two cycles and 33 have been evaluated. No corticosteroids were administered concurrently. An objective response (seven complete and seven partial remissions) was observed in 14 out of 33 patients (42%). Six stable disease cases were also noted. A complete response (5-14 months) was observed in breast cancer [4], lung cancer [1], and melanoma [2]. Seven partial responses lasted 2-5 months. Antitumorigenic activity of Cis DDP was also noted in extracerebral tumor lesions, especially in breast cancer patients. Toxicity was moderate but tolerable. The results of this study have shown Cis DDP to possess antitumorigenic properties also in patients with metastatic brain tumors, a point that has not been proved so far.
Subject(s)
Brain Neoplasms/drug therapy , Cisplatin/therapeutic use , Adenocarcinoma/pathology , Adult , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/secondary , Breast Neoplasms/pathology , Carcinoma, Squamous Cell/pathology , Clinical Trials as Topic , Female , Humans , Lung Neoplasms/pathology , Male , Melanoma/pathology , Middle Aged , RadiographyABSTRACT
In spite of pharmacokinetic studies, which have shown that only cis-DDP traces are found in brain tissue, cytotoxic activity of this drug in primary brain tumors has recently been reported. The purpose of our study was to examine whether cis-DDP aslo has antitumor properties in metastatic brain tumors. Twelve consecutive untreated patients with brain metastases recorded by CAT scans or radionuclide scans plus neurologic examinations underwent the treatment. Histology of primaries revealed 4 bronchial, 3 breast, 1 gastric, 2 colorectal carcinoma, 2 melanomas, and 1 soft tissue sarcoma. Cis-DDP was administered at the doses of 30 mg/m2 body surface daily for 4 days. All the patients were evaluated. Objective response (3 complete and 2 partial remissions) was observed in 5 of 12 patients (response rate 42%). Three stable disease cases were also noted; however, in the remaining 4 patients the disease in the brain progressed. Complete response (5 months) was observed in a breast cancer patient, in a melanoma (4+ months), and in a microcellular bronchial cancer (2+ months). Two partial responses (lung, breast) lasted 2+ and 2+ months. Toxicity was moderate but tolerable for the patients. The preliminary results of this study show that cis-DDP possesses antitumorigenic properties also in patients with metastatic brain tumors, which has not been proved till now.
